Clinical Trials Logo

Filter by:
NCT ID: NCT04742192 Completed - Clinical trials for Non-small Cell Lung Cancer

Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer

EARLY-EGFR
Start date: March 4, 2021
Phase:
Study type: Observational

This prospective, multicountry, multicentre, non-interventional study plans to include patients who have undergone surgery for early-stage (IA to IIIB on the basis of pathologic criteria) non-squamous NSCLC up to 6 weeks prior to enrolment into the study. The main objective of this study is to determine the prevalence of EGFRm in patients with surgically resected early-stage (IA to IIIB) non-squamous NSCLC as there are limited data on its prevalence in this patient population.

NCT ID: NCT04737148 Completed - Burns Clinical Trials

Analysis and Accuracy of Mortality Prediction Scores

Start date: February 20, 2020
Phase:
Study type: Observational

Patients admitted to the ICU in a tertiary burn centre in Kuwait were analysed using multiple mortality prediction scores. The accuracy of these scores were compared to each other to ascertain which prediction modality provides the most accurate prognosis.

NCT ID: NCT04665830 Completed - Clinical trials for Kideny Transplant Recipients With High Cardiovascular Risk Score

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

Start date: May 1, 2018
Phase: Phase 3
Study type: Interventional

From this randomized controlled study, we aim to: A.Do do cardiovascular risk stratification of renal transplant recipients who are followed up in Hamed Al-Essa organ transplant center of Kuwait. B. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy vs. maximum tolerated statin therapy alone in the reduction of major cardiovascular events among renal transplant recipients with cardiovascular disease. C. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy vs. maximum tolerated statin therapy alone in terms of LDL-C-lowering, muscle symptoms, and quality of life. D. To compare patient adherence to the different treatment protocols.

NCT ID: NCT04637633 Completed - Epiphora Clinical Trials

Topical Cyclosporine-A for Management of Epiphora

CSA-epiphora
Start date: August 15, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora in eyes with acquired punctum stenosis

NCT ID: NCT04542954 Completed - Covid19 Clinical Trials

Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East

OMC-KTR
Start date: March 1, 2020
Phase:
Study type: Observational [Patient Registry]

Methods: Out of 2000 kidney transplant recipients in our center in Kuwait, collecting data was started for all COVID-19-positive kidney transplant recipients till August 2020. Clinical features, management details and both patient and graft outcomes were reported.

NCT ID: NCT04497597 Completed - Clinical trials for Rheumatoid Arthritis (RA)

A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

UPHOLD
Start date: October 16, 2020
Phase:
Study type: Observational

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally managed, with sustained clinical remission rarely achieved. This study will assess the treatment patterns, achievement of treatment targets and maintenance of response. Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis. Adult participants with moderate to severe RA who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 1660 participants will be enrolled this study, worldwide. Participants will not receive Upadacitinib as part of this study, but will be followed for response to treatment for up to 24 months. There may be higher burden for participants in this trial compared to their standard of care. Participants will attend regular visits, every 3 months, during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.

NCT ID: NCT04350723 Completed - COVID-19 Clinical Trials

Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE)

COVI-PRONE
Start date: June 10, 2020
Phase: N/A
Study type: Interventional

The aim of the COVI-PRONE Trial is to determine if early awake prone positioning in COVID-19 patients with hypoxemic respiratory failure; irrespective of the mode of oxygen delivery; reduces the need for invasive mechanical ventilation.

NCT ID: NCT04153253 Completed - Clinical trials for Diabetic Vitreous Hemorrhage

Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

Start date: March 7, 2018
Phase: Phase 4
Study type: Interventional

Prospective study comparing efficacy and safety of intravitreal aflibercept injection and panretinal photocoagulation to early vitrectomy for patients with diabetic vitreous hemorrhage.

NCT ID: NCT04146922 Completed - Clinical trials for Escherichia Coli Bacteremia

Switch to Oral Antibiotics in Gram-negative Bacteremia

SOAB
Start date: October 13, 2019
Phase: N/A
Study type: Interventional

Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have achieved adequate source control, are afebrile and hemodynamically stable for 48 hours or more and have received microbiologically active intravenous therapy for 3-5 days. The bloodstream isolate must be susceptible to amoxicillin, amoxicillin-clavulanate, fluoroquinolones, oral cephalosporins and/or trimethoprim-sulfamethoxazole and the subject must be able to take oral medication directly or through a feeding tube. Exclusions criteria include allergy to all in-vitro active antimicrobials which are available in oral formulations, pregnancy, infective endocarditis, central nervous system infection, terminal illness with expected survival less than 14 days, absolute neutrophil count less than 1,000/ml and hematopoietic or solid organ transplantation within the preceding 90 days. Randomization will be stratified by urinary versus non-urinary source of bacteremia. The primary outcome is treatment failure at 90-days with 10% margin for non-inferiority in the 95% confidence interval around the difference in outcome between the two study groups.

NCT ID: NCT04136730 Completed - Diabetes Clinical Trials

Effects of Home-based Resistance Exercise on Body Composition, Muscle Strength and Glycemic Control in People With Type 2 Diabetes.

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study investigates the effects of home-based resistance exercise training, compared to a control group, on body composition, muscle strength and glycaemic control in people with type 2 diabetes. Half participants will be in the home-based exercise group and half in the control group.